Clinical Trial Update: Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating BRAF and MEK blockade as a re-differentiation therapy for RAi-refractory thyroid carcinoma is ongoing and status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Cancer

Drugs mentioned

• BRAF and MEK blockade

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Thyroid Cancer | Phase 2 | Status: UNKNOWN